Distinct antitumor properties of a type IV collagen domain derived from basement membrane
about
Perlecan protein core interacts with extracellular matrix protein 1 (ECM1), a glycoprotein involved in bone formation and angiogenesisHuman tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrinsInteraction of endostatin with integrins implicated in angiogenesisPhysiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrinIdentification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activityExpression analysis of secreted and cell surface genes of five transformed human cell lines and derivative xenograft tumors.Antiangiogenic gene therapy of cancer: recent developmentsNovel endogenous angiogenesis inhibitors and their therapeutic potentialMammalian collagen IVHuman alpha1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by alpha1beta1 integrin.Lack of collagen XVIII/endostatin exacerbates immune-mediated glomerulonephritis.Opticin exerts its anti-angiogenic activity by regulating extracellular matrix adhesivenessTetrastatin, the NC1 domain of the α4(IV) collagen chain: a novel potent anti-tumor matrikine.Vasculostatin, a proteolytic fragment of brain angiogenesis inhibitor 1, is an antiangiogenic and antitumorigenic factor.Recombinant non-collagenous domain of alpha2(IV) collagen causes involution of choroidal neovascularization by inducing apoptosis.Overexpression of tumstatin in genetically modified megakaryocytes changes the proangiogenic effect of platelets.The anti-tumor properties of two tumstatin peptide fragments in human gastric carcinoma.Tumour vascularization: sprouting angiogenesis and beyondMatrilin-1 is an inhibitor of neovascularization.Inhibitory effects of arresten on bFGF-induced proliferation, migration, and matrix metalloproteinase-2 activation in mouse retinal endothelial cellsAntiangiogenic activity of 2-deoxy-D-glucose.Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growthCharacterization of a non-fibrillar-related collagen in the mollusc Haliotis tuberculata and its biological activity on human dermal fibroblasts.Parstatin, a novel protease-activated receptor 1-derived inhibitor of angiogenesis.Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressorsHeat treatment of retinal pigment epithelium induces production of elastic lamina components and antiangiogenic activity.Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors.The high-molecular-weight kininogen domain 5 is an intrinsically unstructured protein and its interaction with ferritin is metal mediated.Angiogenesis and chronic kidney disease.Validation of Different Systems for Tumstatin Expression and its in-vitro and iv-vivo Activities.Collagens and collagen-related diseases.Regulation of Tumor Angiogenesis and Choroidal Neovascularization by Endogenous Angioinhibitors.Vascular wall extracellular matrix proteins and vascular diseasesArresten, a collagen-derived angiogenesis inhibitor, suppresses invasion of squamous cell carcinoma.New functional roles for non-collagenous domains of basement membrane collagensCellular actions and signaling by endostatin.Reduction of tumstatin in asthmatic airways contributes to angiogenesis, inflammation, and hyperresponsiveness.Alprostadil suppresses angiogenesis in vitro and in vivo in the murine Matrigel plug assayCounterbalancing angiogenic regulatory factors control the rate of cancer progression and survival in a stage-specific manner.Recombinant alpha2(IV)NC1 domain inhibits tumor cell-extracellular matrix interactions, induces cellular senescence, and inhibits tumor growth in vivo.
P2860
Q24295251-7DF9F744-6077-4EA2-8643-B8868E1C0774Q24299560-B3656F04-BB6D-4057-AECA-4B1263904610Q24545535-A7BAF300-3BF7-4474-BA64-6456E3793A5FQ24641850-794E0D0F-6413-44E6-A956-D71702A07DD6Q24652387-2753E862-802F-4D80-8563-0D228B871053Q24803501-5170EE10-2F35-481F-A4AC-AAED48659C64Q24803786-9E92BB3B-7A33-42D0-8F44-FC8A065B45A3Q26781297-999E999E-A05A-46A0-9BE1-11EC96BACF83Q28265884-1969C176-1475-46B7-B89E-26B82A5DDE7BQ28271413-CEBA72DD-2FBB-4174-8A99-0AA54F63957FQ30497785-B9B79CEF-4D83-406A-B490-7FD434875609Q30524624-21AD9443-0D90-452D-9D8C-43B2695F9E11Q31058993-997E0126-CBD3-45FC-93EC-34E532EDAAEAQ33112683-E41B3662-D469-4A1A-91B2-B24E6E379D79Q33237435-B453D9F7-14CF-43B7-8E7C-BC2F8359E62AQ33414123-16527A68-FBA6-440B-97A4-804DDB5901C8Q33554948-2D9F8644-28D5-4D2D-83B3-AE02B8729EE1Q33556162-FDFCAC32-7D7A-433D-92B3-69A616548E88Q33619544-690CD4E9-19AE-444C-997B-977CF79A2D8FQ33685500-AA09EB62-C4FE-4B7C-91D8-62CCDA1AA4AAQ33742196-3D8D5281-4D3D-4AE0-AB38-2EEA12419DA8Q33798648-CDC92660-4A58-47C8-8858-E1CD865A120AQ33805033-686AC899-6082-4B70-B3FF-B71D2C70C6EBQ33824563-2D474B68-DA80-4F70-817D-03D24F54D0A9Q33864448-6F3220C9-7199-44FF-93B1-7BDEAC8C0AA1Q33876100-43526443-89B5-47B4-8009-994188F990B3Q33955200-6BB4857A-9929-473A-8F75-BB3111EC558EQ33977801-20C720F7-AD7B-48AC-A2B5-D56D0CC09BB4Q34075013-F9BEF849-0F5C-457A-8867-2F2C58B33C17Q34102845-A538A94C-A09B-4988-B9B3-4C8202F7E5D4Q34224267-EF572E8C-F67A-428C-A239-D3666512997BQ34230899-9FDFF218-F0DF-471B-9401-7AFA85B09839Q34302541-0D02085D-A9EF-4CB6-96A3-12A6EC805F86Q34507203-020CCA9B-5520-413F-87A5-6C803CE26484Q34958987-EE6D98A5-BAF4-40AC-AD31-1EEFBABF9B17Q35008096-12D41CD7-EF9D-4F69-AA7B-6A193A75DC37Q35010424-8702AD8C-6583-41C2-B64B-5795101EC9F4Q35044927-A4392DB0-38D6-4A24-A4FD-E18C85586647Q35049228-E16B3E24-59E0-475C-9767-0DF6374E39C2Q35083731-8BA3951D-4DBD-4DFA-9760-1B91807596BC
P2860
Distinct antitumor properties of a type IV collagen domain derived from basement membrane
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Distinct antitumor properties of a type IV collagen domain derived from basement membrane
@ast
Distinct antitumor properties of a type IV collagen domain derived from basement membrane
@en
Distinct antitumor properties of a type IV collagen domain derived from basement membrane
@en-gb
Distinct antitumor properties of a type IV collagen domain derived from basement membrane
@nl
type
label
Distinct antitumor properties of a type IV collagen domain derived from basement membrane
@ast
Distinct antitumor properties of a type IV collagen domain derived from basement membrane
@en
Distinct antitumor properties of a type IV collagen domain derived from basement membrane
@en-gb
Distinct antitumor properties of a type IV collagen domain derived from basement membrane
@nl
prefLabel
Distinct antitumor properties of a type IV collagen domain derived from basement membrane
@ast
Distinct antitumor properties of a type IV collagen domain derived from basement membrane
@en
Distinct antitumor properties of a type IV collagen domain derived from basement membrane
@en-gb
Distinct antitumor properties of a type IV collagen domain derived from basement membrane
@nl
P2093
P356
P1476
Distinct antitumor properties of a type IV collagen domain derived from basement membrane
@en
P2093
Colorado PC
Ericksen MB
Grunkemeyer JA
Holthaus KA
Maeshima Y
Stillman IE
P304
21340-21348
P356
10.1074/JBC.M001956200
P407
P577
2000-07-01T00:00:00Z